Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma

HG Kang, BZ Wang, J Zhang, MR Liu, YX Li - Clinics and Research in …, 2017 - Elsevier
Summary Objective The oncogenic PI3K/Akt/mTOR pathway is frequently activated in
hepatocellular carcinoma (HCC). The aim of this study is to investigate the anti-HCC effect of …
被引用次数：12 相关文章

Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma

HG Kang, BZ Wang, J Zhang… - Clinics and research …, 2017 - pubmed.ncbi.nlm.nih.gov
Objective The oncogenic PI3K/Akt/mTOR pathway is frequently activated in hepatocellular
carcinoma (HCC). The aim of this study is to investigate the anti-HCC effect of combination …

Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma.

HG Kang, BZ Wang, J Zhang, MR Liu… - Clinics and Research in …, 2016 - europepmc.org
Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in
hepatocellular carcinoma. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …